Role of protein phosphatase-2A and -1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain - PubMed (original) (raw)

Role of protein phosphatase-2A and -1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain

M Bennecib et al. FEBS Lett. 2000.

Free article

Abstract

In Alzheimer disease brain the activities of protein phosphatase (PP)-2A and PP-1 are decreased and the microtubule-associated protein tau is abnormally hyperphosphorylated at several sites at serine/threonine. Employing rat forebrain slices kept metabolically active in oxygenated artificial CSF as a model system, we investigated the role of PP-2A/PP-1 in the regulation of some of the major abnormally hyperphosphorylated sites of tau and the protein kinases involved. Treatment of the brain slices with 1.0 microM okadaic acid inhibited approximately 65% of PP-2A and produced hyperphosphorylation of tau at Ser 198/199/202, Ser 396/404 and Ser 422. No significant changes in the activities of glycogen synthase kinase-3 (GSK-3) and cyclin dependent protein kinases cdk5 and cdc2 were observed. Calyculin A (0.1 microM) inhibited approximately 50% PP-1, approximately 20% PP-2A, 50% GSK-3 and approximately 30% cdk5 but neither inhibited the activity of cyclin AMP dependent protein kinase A (PKA) nor resulted in the hyperphosphorylation of tau at any of the above sites. Treatment of brain slices with 1 microM okadaic acid plus 0.1 microM calyculin A inhibited approximately 100% of both PP-2A and PP-1, approximately 80% of GSK-3, approximately 50% of cdk5 and approximately 30% of cdc2 but neither inhibited PKA nor resulted in the hyperphosphorylation of tau at any of the above sites. These studies suggest (i) that PP-1 upregulates the phosphorylation of tau at Ser 198/199/202 and Ser 396/404 indirectly by regulating the activities of GSK-3, cdk5 and cdc2 whereas PP-2A regulates the phosphorylation of tau directly by dephosphorylation at the above sites, and (ii) that a decrease in the PP-2A activity leads to abnormal hyperphosphorylation of tau at Ser 198/199/202, Ser 396/404 and Ser 422.

PubMed Disclaimer

Cited by

PP2A-Mediated GSK3β Dephosphorylation Is Required for Protocadherin-7-Dependent Regulation of Small GTPase RhoA in Osteoclasts.
Kim H, Takegahara N, Choi Y. Kim H, et al. Cells. 2023 Jul 29;12(15):1967. doi: 10.3390/cells12151967. Cells. 2023. PMID: 37566044 Free PMC article.
Probiotic supplement as a promising strategy in early tau pathology prevention: Focusing on GSK-3β?
Flynn CM, Yuan Q. Flynn CM, et al. Front Neurosci. 2023 Mar 22;17:1159314. doi: 10.3389/fnins.2023.1159314. eCollection 2023. Front Neurosci. 2023. PMID: 37034173 Free PMC article. Review.
Tau and neurodegenerative disease: the story so far.
Iqbal K, Liu F, Gong CX. Iqbal K, et al. Nat Rev Neurol. 2016 Jan;12(1):15-27. doi: 10.1038/nrneurol.2015.225. Epub 2015 Dec 4. Nat Rev Neurol. 2016. PMID: 26635213 Review.
Protein Phosphatase 2A as a Therapeutic Target in Pulmonary Diseases.
Yu H, Zaveri S, Sattar Z, Schaible M, Perez Gandara B, Uddin A, McGarvey LR, Ohlmeyer M, Geraghty P. Yu H, et al. Medicina (Kaunas). 2023 Aug 26;59(9):1552. doi: 10.3390/medicina59091552. Medicina (Kaunas). 2023. PMID: 37763671 Free PMC article. Review.
Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling.
Kickstein E, Krauss S, Thornhill P, Rutschow D, Zeller R, Sharkey J, Williamson R, Fuchs M, Köhler A, Glossmann H, Schneider R, Sutherland C, Schweiger S. Kickstein E, et al. Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21830-5. doi: 10.1073/pnas.0912793107. Epub 2010 Nov 22. Proc Natl Acad Sci U S A. 2010. PMID: 21098287 Free PMC article.

Role of protein phosphatase-2A and -1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain - PubMed (original) (raw)